#acute myeloid leukemia

The Latest Advancements in Immunotherapy for Adult Leukemia

Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.

A small group of adults in remission had persisting mutations that predicted their risk of death from having the cancer return.

For Steve Buechler, terms like “journey” and “battle” fail to describe his experiences with leukemia. Other people with cancer agree.

Meet the eight innovative scientists and learn about the research Damon Runyon is funding.

A team of experts on acute promyelocytic leukemia (APL) were available by phone or email to other oncologists treating this rare cancer.

Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.

"This is almost double what was previously estimated,” researchers said of the number of Californians who died of tobacco-related cancers.

The test shows which patients with clonal hematopoiesis, a precancerous state, are more likely to develop blood cancers.

Rezlidhia (olutasidenib) is approved as a targeted treatment option for adults whose acute myeloid leukemia carries the IDH1 mutation.

Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.

James DeGregori, PhD, led research that revealed the role of the mTOR signaling pathway in AML treatment.

African Americans between 18 and 39 with acute myeloid leukemia are more likely to die within five years compared with white people.

This two-time cancer survivor and former health reporter believes “pre-habilitation” can prepare you for any health crisis.

With omicron surging in February, Suleika Jaouad’s husband Jon Batiste couldn’t be with her in the hospital.

“We were favorably surprised by the quality of tumor responses in patients."

A new study clarifies the benefits and risks of treatments for those with multiple myeloma, a blood cancer more common in Black Americans.